Antigen diluent and immunodeficiency virus detection kit
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A protective agent, dimethyldiacetoxysilane technology, applied in the field of medicine and biology, can solve the problems of low accuracy, stability and repeatability, and achieve the effect of improving stability and repeatability
Pending Publication Date: 2022-03-01
SHANGHAI CHEMTRON BIOTECH
View PDF0 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0004] Up to now, HIV test kits that use urine as a specimen on the market have low accuracy, low stability and low repeatability
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0045] See the preparation process of the test kit figure 2 The specifically followed:
[0046] 1) Preparation of antigen dilution: with volume parts, PBS buffer (by NA 2 HPO 4 , Nah 2 PO 4 NaOH, C 6 Hide 5 NA 3 O 7 It was prepared from NaCl in deionized water to obtain 15 parts of, 15 calf serum, and the protective agent dimethyl acetyloxysilane was 0.2 parts of ICD hybrid;
[0047] 2) Preparation of immunoplease particle paper: The reaction buffer is added to the latex solution, and the reaction buffer is a mixture of antigen dilution and HIV-1GP41 antigen, HIV-2GP36 antigen, the mixture of 7.0, and antigen in the mixture The labeled concentration is 7 μg / ml, using a centrifuge to concentrate the marked immune latex; a quantity of phosphate buffer is added to a specified volume according to the product requirements in a concentrated immunoplasmic solution.
[0048] 3) Preparation of nitrocellulose films: contains a quality control line and a detection line, wherein the quality...
Embodiment 2
[0051] Other operation steps are consistent with Embodiment 1, and the difference is: step 1), with volume parts, PBS buffer (by NA) 2 HPO 4 , Nah 2 PO 4 NaOH, C 6 Hide 5 NA 3 O 7 It was prepared from NaCl in deionized water to prepares 80 parts, 25 parts of calf serum, and the protective agent dimethyl diacetyloxysilane is 0.1 parts of the ICD.
Embodiment 3
[0053] Other operation steps are consistent with Embodiment 1, and the difference is: step 1), with volume parts, PBS buffer (by NA) 2 HPO 4 , Nah 2 PO 4 NaOH, C 6 Hide 5 NA 3 O 7 It was prepared from NaCl in deionized water to prepare for 77 parts, 20 calf serum, and the protective agent dimethyl acetyloxysilane was 0.15 parts of the ICD.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention provides an antigen diluent and an immunodeficiency virus detection kit, the antigen diluent is mainly composed of a PBS buffer solution, calf serum and a protective agent, the protective agent comprises dimethyl diacetoxysilane, Ectoin and a synergistic protective agent, the synergistic protective agent is prepared from any one of erdosteine, thiomersalate, S-allyl mercaptocysteine and mercaptopyridoxine or a mixture of more of erdosteine, thiomersalate, S-allyl mercaptocysteine and mercaptopyridoxine. According to the antigen diluent, the protective agent capable of enabling the antigen and the antibody to have relatively high activity is added, and the types of the protective agent are screened and reasonably proportioned and mixed, so that after the antigen diluent is adopted, the stability and the accuracy of an immunological detection device are remarkably improved, and the antigen diluent is worthy of wide popularization and application.
Description
Technical field [0001] The present invention relates to the field of pharmaceutical biological, and in particular, to an antigen diluent and an immunodeficiency detection kit. Background technique [0002] Human immunodeficiency viruses are chronic diseases infected with human immune system cells, belonging to the reverse transcription virus, divided into two major types of HIV-1 and HIV-2 depending on their genotypes. HIV is destroyed by t lymphocytes in the human body, and thereby blocking the cellular immunity and body fluid immune process, causing the immune system to be paralyzed, thus causing all kinds of diseases spread in the human body, eventually leading to AIDS. [0003] Currently, there are many types of methods for detecting HIV, mainly including HIV antibodies and HIV nucleic acid detection. The detected specimens can detect anti-HIV in addition to blood, urine, saliva, tears, semen and vaginal secretions. As an important part of the blood as an internal environment...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more